Gemcitabine/Cisplatin for Resected Pancreas Cancer: Establishing the Role of Excision Repair Cross Complementation Gene 1(ERCC1)in Treatment Decision

Inclusion Criteria:

1. Adults (> 18 years) at the time of signing informed consent form

2. Understand and voluntarily sign informed consent form

3. Able to adhere to study visit schedule and other protocol requirements

4. ECOG performance status of ≤ 2

5. Absolute neutrophil count ≥ 1500 / mm3

6. Platelet count ≥ 100,000 / mm3

7. Resectable pancreatic adenocarcinoma

8. Pathologic diagnosis of pancreatic adenocarcinoma

Exclusion Criteria:

1. Any serious medical condition, laboratory abnormality, or psychiatric illness that
would prevent the subject from signing informed consent form

2. A history of renal dysfunction (Serum Creatinine > 1.8 mg/dL)

3. Presence of active infection

4. Untreated second malignancy

5. Pregnant or breast feeding females